These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 24600280)

  • 21. A review of the rationale and clinical utilization of α2-adrenoceptor agonists for the treatment of attention-deficit/hyperactivity and related disorders.
    Sallee F; Connor DF; Newcorn JH
    J Child Adolesc Psychopharmacol; 2013 Jun; 23(5):308-19. PubMed ID: 23782125
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety limitations of attention-deficit hyperactivity disorder pharmacotherapy in children and adults.
    Wigal SB
    CNS Drugs; 2009; 23 Suppl 1():21-31. PubMed ID: 19621975
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
    Boesen K; Paludan-Müller AS; Gøtzsche PC; Jørgensen KJ
    Cochrane Database Syst Rev; 2022 Feb; 2(2):CD012857. PubMed ID: 35201607
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical utility of guanfacine extended release in the treatment of ADHD in children and adolescents.
    Bello NT
    Patient Prefer Adherence; 2015; 9():877-85. PubMed ID: 26170637
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Role of Alpha-2 Agonists for Attention Deficit Hyperactivity Disorder in Children: A Review.
    Neuchat EE; Bocklud BE; Kingsley K; Barham WT; Luther PM; Ahmadzadeh S; Shekoohi S; Cornett EM; Kaye AD
    Neurol Int; 2023 May; 15(2):697-707. PubMed ID: 37218982
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Phase 3, Randomized Double-Blind Study of the Efficacy and Safety of Low-Dose SHP465 Mixed Amphetamine Salts Extended-Release in Children with Attention-Deficit/Hyperactivity Disorder.
    Mattingly G; Arnold V; Yan B; Yu M; Robertson B
    J Child Adolesc Psychopharmacol; 2020 Nov; 30(9):549-557. PubMed ID: 33185468
    [No Abstract]   [Full Text] [Related]  

  • 27. Efficacy and safety of mixed amphetamine salts extended release (adderall XR) in the management of oppositional defiant disorder with or without comorbid attention-deficit/hyperactivity disorder in school-aged children and adolescents: A 4-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled, forced-dose-escalation study.
    Spencer TJ; Abikoff HB; Connor DF; Biederman J; Pliszka SR; Boellner S; Read SC; Pratt R
    Clin Ther; 2006 Mar; 28(3):402-18. PubMed ID: 16750455
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of alpha2-adrenergic agonists in attention-deficit/hyperactivity disorder.
    Sallee FR
    Postgrad Med; 2010 Sep; 122(5):78-87. PubMed ID: 20861591
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d-amphetamine, for the treatment of attention-deficit/hyperactivity disorder in children and adults.
    Najib J
    Clin Ther; 2009 Jan; 31(1):142-76. PubMed ID: 19243715
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: A systematic review with network meta-analyses of randomised trials.
    Catalá-López F; Hutton B; Núñez-Beltrán A; Page MJ; Ridao M; Macías Saint-Gerons D; Catalá MA; Tabarés-Seisdedos R; Moher D
    PLoS One; 2017; 12(7):e0180355. PubMed ID: 28700715
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Polypharmacy in the Management of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents: A Review and Update.
    Baker M; Huefner JC; Bellonci C; Hilt R; Carlson GA
    J Child Adolesc Psychopharmacol; 2021 Apr; 31(3):148-163. PubMed ID: 33600217
    [No Abstract]   [Full Text] [Related]  

  • 32. Effects of guanfacine extended release on oppositional symptoms in children aged 6-12 years with attention-deficit hyperactivity disorder and oppositional symptoms: a randomized, double-blind, placebo-controlled trial.
    Connor DF; Findling RL; Kollins SH; Sallee F; López FA; Lyne A; Tremblay G
    CNS Drugs; 2010 Sep; 24(9):755-68. PubMed ID: 20806988
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of Children and Adolescents with Attention Deficit Hyperactivity Disorder and/or Tourette's Disorder with Clonidine Extended Release.
    Joo SW; Kim HW
    Psychiatry Investig; 2018 Jan; 15(1):90-93. PubMed ID: 29422931
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Atomoxetine (Strattera), an alternative in the treatment of attention-deficit/hyperactivity disorder (ADHD) in children].
    Gaillez C; Sorbara F; Perrin E
    Encephale; 2007 Sep; 33(4 Pt 1):621-8. PubMed ID: 18033153
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Atypical antipsychotics for disruptive behaviour disorders in children and youths.
    Loy JH; Merry SN; Hetrick SE; Stasiak K
    Cochrane Database Syst Rev; 2012 Sep; (9):CD008559. PubMed ID: 22972123
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative efficacy of guanfacine extended release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: applying matching-adjusted indirect comparison methodology.
    Sikirica V; Findling RL; Signorovitch J; Erder MH; Dammerman R; Hodgkins P; Lu M; Xie J; Wu EQ
    CNS Drugs; 2013 Nov; 27(11):943-53. PubMed ID: 23975660
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost effectiveness of guanfacine extended release as an adjunctive therapy to a stimulant compared with stimulant monotherapy for the treatment of attention-deficit hyperactivity disorder in children and adolescents.
    Sikirica V; Haim Erder M; Xie J; Macaulay D; Diener M; Hodgkins P; Wu EQ
    Pharmacoeconomics; 2012 Aug; 30(8):e1-15. PubMed ID: 22788263
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Meta-analysis: treatment of attention-deficit/hyperactivity disorder in children with comorbid tic disorders.
    Bloch MH; Panza KE; Landeros-Weisenberger A; Leckman JF
    J Am Acad Child Adolesc Psychiatry; 2009 Sep; 48(9):884-893. PubMed ID: 19625978
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.